Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion.
In: Financial News Releases, 2023-02-02, S. NA
Zeitungsartikel
Zugriff:
Titel: |
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion.
|
---|---|
Zeitschrift: | Financial News Releases, 2023-02-02, S. NA |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|